Limitations, agreements, and source contact

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease · Source last updated 2023-12-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

restrictive Agreement

false

limitations And Caveats

description

Mix of previously treated \& newly diagnosed pts (populations which may have different prognoses), plus the relatively small trial size limit conclusions one can draw re: relative efficacy of MDV (vs CyBorD or Mel-Dex, for example)

point Of Contact

email

zonderj@karmanos.org

organization

Barbara Ann Karmanos Cancer Institute

phone

313-576-8732

title

Jeffrey Zonder, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice